Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
Richier Q, De Valence B, Chopin D, Gras E, Levi LI, Abi Aad Y, Pacanowski J, Meynard JL, Plaçais L, Fey D, Couture P, Martin-Blondel G, Pestre V, Woessner J, Ancellin S, Weyrich P, Carpentier B, Idri S, Tiberghien P, Surgers L, Hueso T, Lacombe K. Richier Q, et al. Among authors: lacombe k. Influenza Other Respir Viruses. 2024 Mar;18(3):e13272. doi: 10.1111/irv.13272. Influenza Other Respir Viruses. 2024. PMID: 38501337 Free PMC article.
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.
de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group. de Truchis P, et al. J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434. J Antimicrob Chemother. 2018. PMID: 29186458 Clinical Trial.
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.
Wembulua BS, Valin N, Lambert-Niclot S, Nerozzi-Banfi E, Chiarabini T, Meynard JL, Lacombe K. Wembulua BS, et al. Among authors: lacombe k. J Acquir Immune Defic Syndr. 2023 Mar 1;92(3):e17-e18. doi: 10.1097/QAI.0000000000003148. J Acquir Immune Defic Syndr. 2023. PMID: 36729654 No abstract available.
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
Bachelard A, Isernia V, Charpentier C, Benalycherif A, Mora M, Donadille C, Duvivier C, Lacombe K, El Mouhebb M, Spire B, Landman R, Descamps D, Peytavin G, Assoumou L, Ghosn J; FAST study group. Bachelard A, et al. Among authors: lacombe k. J Antimicrob Chemother. 2023 Mar 2;78(3):769-778. doi: 10.1093/jac/dkad008. J Antimicrob Chemother. 2023. PMID: 36659824
The kinetics and durability of antibody and T-cell responses to SARS-CoV-2 in children.
Files MA, Gentles L, Kehoe L, Adler A, Lacombe K, Dickerson JA, Greninger A, Waghmare A, Fairlie T, Pringle K, Midgley CM, Hagen MB, Englund JA, Seshadri C. Files MA, et al. Among authors: lacombe k. J Infect Dis. 2024 Jun 5:jiae301. doi: 10.1093/infdis/jiae301. Online ahead of print. J Infect Dis. 2024. PMID: 38838218
Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: a French nationwide multicenter cohort study - ANRS0001s COV-POPART.
Loubet P, Lelievre JD, François A, Botelho-Nevers E, Chidiac C, Chirio D, Dubee V, Dussol B, Galtier F, Hessamfar M, Hodaj E, Jaffuel S, Lacombe K, Laine F, Lefebvre M, Maakaroun-Vermesse Z, Makinson A, Portefaix A, Pourcher V, Rey D, Zucman D, Longobardi J, Bertheau M, Tartour E, de Lamballerie X, Launay O, Wittkop L; ANRS0001s COV-POPART study group. Loubet P, et al. Among authors: lacombe k. Int J Infect Dis. 2024 May 31:107110. doi: 10.1016/j.ijid.2024.107110. Online ahead of print. Int J Infect Dis. 2024. PMID: 38825164 Free article.
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design.
Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, Katlama C, Surgers L, Bébéar C, Dupin N, Ouattara M, Slama L, Pavie J, Duvivier C, Loze B, Goldwirt L, Gibowski S, Ollivier M, Ghosn J, Costagliola D; ANRS 174 DOXYVAC Study Group. Molina JM, et al. Lancet Infect Dis. 2024 May 23:S1473-3099(24)00236-6. doi: 10.1016/S1473-3099(24)00236-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38797183
Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
Lacombe K, Moh R, Chazallon C, Lemoine M, Sylla B, Fadiga F, Le Carrou J, Marcellin F, Kouanfack C, Ciaffi L, Sartre MT, Sida MB, Diallo A, Gozlan J, Seydi M, Cissé V, Danel C, Girard PM, Toni TD, Minga A, Boyer S, Carrieri P, Attia A; TAC ANRS12311 Study Group. Lacombe K, et al. Sci Rep. 2024 May 3;14(1):10244. doi: 10.1038/s41598-024-57013-1. Sci Rep. 2024. PMID: 38702350 Free PMC article. Clinical Trial.
379 results